Prenatal genetic screening: when to test for immune defects

The conversation I keep having with genetics counselors goes something like this: a couple arrives after losing a first child to severe combined immunodeficiency, the causative variant already sequenced, and they want to know what their next pregnancy looks like before the second trimester. That question has a clear, defensible answer. What does not have a clean answer is the email I get every few weeks from a couple with no family history asking whether the cell-free DNA screen from their first-trimester visit picked up anything related to immune disorders. It didn't, because routine NIPT for single-gene primary immunodeficiencies is not part of standard screening for low-risk pregnancies. That distinction — between targeted prenatal diagnosis for known familial variants and broad population screening — is the single most important thing to get straight before anyone books a procedure.

So let's walk through what prenatal genetic testing for primary immunodeficiency actually covers, who qualifies, what the procedures entail, and where the evidence on clinical utility actually stands.

Who Actually Qualifies for Targeted Prenatal Analysis

Prenatal diagnosis for primary immunodeficiencies (PIDs, now increasingly called inborn errors of immunity, or IEIs) is not a population-level offering. In my experience auditing these requests, the eligibility criteria narrow quickly. The trigger is always the same: a previously affected family member — an index case — with an identified pathogenic gene mutation.

That means one of two scenarios has typically occurred before any fetal sample is taken:

• A first child has presented with a confirmed PID (most commonly SCID, but also the broader spectrum of combined immunodeficiencies, agammaglobulinemias, and defined monogenic immune dysregulation syndromes), and the causative variant has been characterized through clinical exome or targeted panel sequencing.
• A parent has been identified as a carrier of a known PID-causing variant, often during workup after the index case diagnosis, sometimes through expanded carrier screening that included immune genes.

Without a characterized variant in the family, the analytical validity of any targeted fetal sequencing collapses. You're not screening for "immune problems" — you're testing for a specific mutation. The distinction matters because turnaround, sensitivity, and clinical actionability all depend on it.

Targeted prenatal PID testing is variant-specific, not disease-specific. Without a known family mutation, the test has nothing to anchor to.

The prevalence figures often cited — primary immunodeficiencies affecting somewhere between 1 in 1,000 and 1 in 5,000 live births depending on how broadly you count — obscure the practical reality that most of these conditions are too rare and too genetically heterogeneous for population-wide prenatal screening. The 450-plus distinct inborn errors of immunity currently catalogued (with IUIS updates continuing to expand the list) each carry their own prevalence, and the vast majority sit well below the threshold where universal prenatal screening would be cost-effective or analytically tractable.

Standard Procedures for Fetal Genomic DNA Collection

When a familial variant is in hand, two procedures carry essentially all the diagnostic weight: chorionic villus sampling (CVS) and amniocentesis. Both are invasive, both carry procedure-related risks that need to be discussed honestly with the family, and both yield fetal DNA suitable for targeted sequencing or, where appropriate, broader exome analysis.

CVS is typically performed between 11 and 14 weeks of gestation and samples placental tissue. The earlier window is clinically meaningful — a family who lost a previous child to SCID and wants to know before the second trimester will often push for CVS specifically because of that timing. Amniocentesis comes slightly later, generally from 15 weeks onward, and samples amniotic fluid containing fetal cells.

A few practical points worth stating clearly:

• Turnaround times for targeted sequencing on either sample type generally fall in the 10-to-33-day window, depending on the lab, the gene panel size, and whether confirmation by an orthogonal method is required.
• Mosaicism is a known limitation of CVS in particular — confined placental mosaicism can produce results that do not reflect fetal genotype. Labs typically flag this and recommend amniocentesis confirmation when CVS findings are ambiguous.
• Both procedures carry procedure-related risks — chiefly pregnancy loss — that need to be discussed honestly with the family. The absolute loss rates are small but not trivial when the procedure is being done for a condition that itself may be treatable postnatally.

There's also a non-invasive option that gets raised in consultations — cell-free fetal DNA analysis from maternal blood. For sex determination and common aneuploidies, NIPT is robust. For single-gene PIDs in a low-risk pregnancy without a known variant, it's not validated, not recommended, and not analytically adequate. The unknowns section of any current guideline is unambiguous on this. Where NIPT does have emerging evidence is in tracking a previously characterized familial variant in maternal plasma, but that's a research-grade application, not a clinical service for general prenatal care.

Phenotypic Cordocentesis in Late-Stage Diagnostics

Not every case arrives with months of lead time. Sometimes a couple presents late in the second trimester — 22, 24, even 26 weeks — and the clinical picture suggests an immune defect but no molecular variant was ever identified in a previously affected child, or there was no previously affected child and the suspicion is raised on ultrasound or family history discovered late.

In these scenarios, cordocentesis — ultrasound-guided fetal blood sampling from the umbilical vein — combined with flow cytometry can offer a phenotypic readout of the fetal immune system. Specifically, you can quantify T-cell, B-cell, and NK-cell populations and compare them against gestational-age-adjusted reference ranges. A severely depleted CD3+ T-cell count at 20-plus weeks is a strong phenotypic signal for SCID or severe combined immune phenotypes.

The limitations are real and worth naming:

• Reference ranges for fetal lymphocyte subsets are not as standardized as newborn reference ranges.
• The procedure is technically demanding and carries a higher loss rate than CVS or amniocentesis.
• Phenotype does not equal genotype. A T-cell depletion pattern narrows the differential but does not name the gene.

In practice, cordocentesis flow cytometry is the option when molecular diagnosis isn't available and the gestational clock is ticking. It's not a first-line tool. For most families with a previously characterized variant, targeted molecular testing on CVS or amniocentesis samples remains the higher-yield path.

Phenotypic cordocentesis answers "is the fetal immune system abnormal?" — molecular testing on CVS or amniocytes answers "does this fetus carry the family's specific pathogenic variant?" These are different questions.

Clinical Utility of Early SCID Identification

Here's where the case for prenatal PID diagnosis gets its clinical teeth. Severe combined immunodeficiency is the flagship indication because the post-diagnostic management pathway is concrete and time-sensitive. A fetus identified as carrying a pathogenic SCID-causing variant — including variants in IL2RG, JAK3, RAG1, RAG2, ADA, and a handful of other well-characterized genes — can trigger a defined set of perinatal interventions:

• Avoidance of live vaccines, particularly rotavirus and BCG where relevant, until immune status is confirmed postnatally.
• Protective infection control planning, including isolation protocols at delivery and avoidance of crowded pediatric waiting rooms.
• Early hematopoietic stem cell transplantation (HSCT), which has dramatically better outcomes when performed before 3.5 months of age and before the onset of significant infectious complications.

The outcome data on early HSCT for SCID is one of the stronger success stories in pediatric immunology. Modern cohorts consistently show that survival post-transplant is significantly better when the procedure is performed before 3.5 months of age and before the infant has acquired significant infections. Delayed transplantation — or transplantation after active infection has set in — materially worsens the prognosis, and the difference is not marginal.

Prenatal diagnosis doesn't replace newborn screening. It complements it. The TREC-based newborn screen for SCID, now standard across most of the United States and an expanding list of other countries, catches the majority of SCID cases regardless of family history. What prenatal diagnosis adds is the lead time — weeks to months — that allows a delivery plan to be in place rather than assembled emergentially after an abnormal newborn screen. For families who already know they're at risk, that lead time has real clinical value.

Navigating Diagnostic Timelines and IUIS Classification

The diagnostic taxonomy matters operationally because it determines which genes sit on the targeted panel. The International Union of Immunological Societies (IUIS) currently organizes inborn errors of immunity into 10 major phenotypic categories, with the most recent published update landing in 2024 and continued panel expansion through 2025–2026. These categories run from combined immunodeficiencies (where SCID sits) through syndromes with prominent immune features, antibody deficiencies, immune dysregulation, phagocyte defects, complement deficiencies, and others.

For a clinician building a targeted panel for a specific family, the IUIS classification does the heavy lifting of ensuring the right genes are covered. The breadth of the panel — focused versus comprehensive — should match what was identified in the index case. A family with a known IL2RG variant needs a tightly targeted assay, not a broad immune panel. A family where the index case was clinically diagnosed but never molecularly characterized is in a different situation entirely, and that's where broader exome-based approaches with appropriate trio analysis (both parents plus the fetal sample) become relevant.

A practical timeline consideration: the diagnostic window is tighter than many families expect. CVS results at 12 weeks, amniocentesis at 16–18 weeks, cordocentesis if needed at 20-plus weeks. Add 10 to 33 days for sequencing turnaround. By the time a result is in hand, decisions about continuation, delivery planning, and perinatal team notification need to be made quickly. Labs that offer expedited prenatal panels for known familial variants exist, but the bottleneck is more often the clinical coordination than the sequencing itself.

There's also a regulatory consideration that doesn't get discussed enough in prenatal counseling. Variants of uncertain significance (VUS) are a real possibility, particularly when a targeted panel returns a novel or rare missense variant. The clinical actionability of a VUS in the prenatal setting is genuinely limited — you generally cannot base delivery planning on a VUS, and reporting practices vary between labs. Families should be counseled on this before testing, not after.

Where This Leaves the Clinician

Prenatal genetic testing for primary immunodeficiency is a targeted, indication-driven service — not a screening program. It works well when a familial pathogenic variant is already characterized and the question is binary: does this fetus carry it or not. In that scenario, the diagnostic pathway is well-established, the analytical sensitivity is high, and the clinical utility — particularly for SCID — is supported by outcome data on early intervention.

Outside that scenario, the test loses its anchor. Routine NIPT does not screen for single-gene PIDs, and there is no current professional society recommendation to offer such screening in low-risk pregnancies. The most defensible position for any clinician counseling a couple without a known family history is to redirect them toward newborn screening, which catches the bulk of clinically significant SCID cases regardless of genetic anticipation.

For families with a known variant, the workflow is clear: targeted sequencing on CVS or amniocentesis, with cordocentesis flow cytometry reserved for late-presenting cases without a characterized mutation. The earlier the result, the more clinically actionable the perinatal planning — particularly for SCID, where HSCT outcomes are tightly linked to pre-symptomatic transplantation.

The hype around prenatal genomic medicine is real, and the consumer-facing marketing has outpaced the evidence in several areas. Prenatal PID testing is not one of those areas. It is a specific tool for a specific clinical situation, and used as such, it does what it claims to do.